1986
DOI: 10.1002/1097-0142(19860801)58:3<617::aid-cncr2820580304>3.0.co;2-1
|View full text |Cite
|
Sign up to set email alerts
|

A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia: A leukemia-lymphoma group trial of the EORTC

Abstract: Twenty-three European centers participated in a randomized clinical trial (AML-5) to study the effect of androgens and immunotherapy during maintenance in adult acute myelogenous leukemia. Induction treatment consisted of Adriamycin (doxorubicin) 50 mg/m2 day 1, vincristine VCR 1 mg/m2 day 2, and cytosine arabinoside 80 mg/m2 every 12 hours by push injection days 3-9. Patients in complete remission were randomized into four groups: (1) 6-mercaptopurine 70 mg/m2 days 1-14, methotrexate 15 mg/m2 twice weekly day… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

1987
1987
2021
2021

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 42 publications
(4 citation statements)
references
References 22 publications
0
4
0
Order By: Relevance
“…The age‐related study results are listed in Table 1 in the order of increasing age in the groups of patients treated (16–27, 30–40, 43–48). If age specific therapeutic results were reported, the related publications were listed for separate age groups.…”
Section: Age and Trends In Chemotherapymentioning
confidence: 99%
See 1 more Smart Citation
“…The age‐related study results are listed in Table 1 in the order of increasing age in the groups of patients treated (16–27, 30–40, 43–48). If age specific therapeutic results were reported, the related publications were listed for separate age groups.…”
Section: Age and Trends In Chemotherapymentioning
confidence: 99%
“…While Table 1 provides a synopsis of different treatment modalities, differences between the trials must be interpreted with caution. As children were included in some trials (17, 18, 20, 33, 34, 36) or various proportions of patients became excluded at the occasion of randomization in remission (17, 19, 21, 23, 35, 36, 38, 45, 47, 48) fair interstudy comparisons are certainly compromized by unknown selection factors.…”
Section: Age and Trends In Chemotherapymentioning
confidence: 99%
“…Androgens have been demonstrated to be useful in treating aplastic anemia since the late 1970s, [12][13][14][15] which led to testing these drugs in the treatment of AML with some success [16][17][18] in the 1980s. Most of these studies, however, were monocentric or had insufficient statistical power because of a low number of enrolled patients.…”
Section: Introductionmentioning
confidence: 99%
“…A marginally significant better relapse-free survival was noted. In an EORTC randomized trial, no significant beneficial effect on disease-free survival was noted for the group of AML patients who received immunotherapy with irradiated blasts, although these patients seemed to have higher response rates to re-induction of chemotherapy after relapse [84]. In a randomized study, on 64 patients with myelogenous leukemia who entered complete remission with chemotherapy, the administration of neuraminidase-treated allogenic blasts improved the median relapse-free survival from 15 to 40 months [85].…”
Section: The Era Of Active Specific Immunotherapymentioning
confidence: 98%